New Antidepressant: Vortioxetine Approved in the U.S.

On September 30th, 2013, the U.S. Food and Drug Administration (FDA) approved vortioxetine (Brintellix ®; previously Lu AA21004) for the treatment of depressive disorders. Approval from the European Medicines Agency (EMA) was requested in September 2012. Thus, approval in the EU can be expected soon. The substance was also assessed for the treatment of Generalized Anxiety Disorder (GAD). Vortioxetine is marketed by Takeda and Lundbeck. Continue reading